A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-30

Study Completion Date

2024-07-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand how the loss of kidney function affects study medicine (PF-07923568) in the body. People with some level of loss of kidney function may process PF-07923568 differently from healthy people. PF-07923568 is developed as a possible treatment for respiratory syncytial virus (RSV) infection. RSV is a common virus that affects the lungs and usually causes mild, cold-like symptoms. RSV can cause severe lung infections in infants, elderly, and adults with other serious medical conditions.

This study is seeking participants who:

* Have less than 25% difference in kidney function between 2 screening visits.
* Meet the eGFR criteria for being assigned to groups. eGFR tells how well the kidney is filtering.
* Are not on hemodialysis. Hemodialysis is a type of treatment that helps the body remove extra fluid and waste products from the blood when the kidneys are not able to.

Participants will take the study medicine as capsules by mouth once at the study clinic. The participants will stay at the study clinic for about 5 days. During that time, the study team will monitor the participants. The study team will take some blood samples to test the level of PF-07923568. This will help us understand if some level of loss of kidney function will have an effect on the study medicine PF-07923568.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

NCT04909853

Renal Impairment

COMPLETED PHASE1

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

NCT06586216

COVID-19

COMPLETED PHASE1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

NCT07315360

Renal Impairment Healthy

NOT_YET_RECRUITING PHASE1

A Renal Impairment Study for PF-04965842

NCT03660241

Renal Impairment

COMPLETED PHASE1

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

NCT00596518

Renal Insufficiency, Chronic

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: Severe Renal Impairment

Participants with severe renal impairment will receive a single oral dose of PF-07923568

Group Type EXPERIMENTAL

Drug: PF-07923568

Intervention Type DRUG

A single dose of PF-07923568 administered orally as 4 capsules

Cohort 2: Normal Renal Function

Participants with normal renal function will receive a single oral dose of PF-07923568

Group Type EXPERIMENTAL

Drug: PF-07923568

Intervention Type DRUG

A single dose of PF-07923568 administered orally as 4 capsules

Cohort 3 (Optional): Moderate Renal Impairment

Participants with moderate renal impairment will receive a single oral dose of PF-07923568

Group Type EXPERIMENTAL

Drug: PF-07923568

Intervention Type DRUG

A single dose of PF-07923568 administered orally as 4 capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug: PF-07923568

A single dose of PF-07923568 administered orally as 4 capsules

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sisunatovir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Stable renal function defined as ≤25% difference between 2 measurements of absolute estimated glomerular filtration rate (eGFR) during screening.
2. Meet the eGFR criteria for cohort placement during the screening period.
3. Body mass index (BMI) of 16-40 kg/m2; and a total body weight \>45 kg (99 lb.).
4. For Cohort 2 Normal Renal Function Group Only: At screening, meet the demographic-matching criteria, including body weight within ±15 kg and age within ±10 years, of the average of the pooled renal impairment cohort.

Exclusion Criteria

1. Participants with acute renal disease.
2. Participants who are clinically nephrotic.
3. Participants requiring hemodialysis.
4. Renal allograft recipients.
5. Participants who have previously received a kidney, liver, or heart transplant.
6. Urinary incontinence without catheterization.
7. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb).
8. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
9. Participation in studies of other investigational products (drug or vaccine) at any time during their participation in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes